Cardiovascular diseases became acquired almost epidemic range during the past decades. For many years they have been the prime cause of people's mortality in a number of economically developed states, including Russia. 60% of all deaths fall on such diseases.
Arterial hypertension (AH), which is tightly connected with various types of strokes (hemorrhagic, ischemic), has the major effect on life duration, of all factors of individual risk of cardiovascular complications.
In Russia, the number of stroke cases and the related mortality remain one of the highest in the world; more than 400 000 cases with 35% first-month lethality are recorded annually.
Prevention of development and progressing of cerebral vascular disorders, as well as improving of life quality of patients, is the key tasks of cardiology, neurology and therapeutics. In this connection, we find it important to search new trends of influence on various components of pathogenesis of ischemic injuries of brain, as well as expanding of the view of action mechanisms of already known medications.
Thereat, Mexidol preparation (2 - ethyl - 6 - methyl - 3 - hydroxypyridine succinate), having a polycomponent range of pharmacological effects and multipurpose mechanism of action, represents a great theoretical and practical interest. In the conditions of ischemic brain injury Mexidol causes anti-hypoxic and antioxidant action, with positive effect on energy production in a cell: reducing output of free radicals and restoring the activity of antioxidant protection enzymes. Mexidol promotes intracellular synthesis of protein and nucleonic acids, fermentation processes of Krebs cycle; activates glucose utilization, synthesis and intracellular accumulation of adenosine triphosphate, which reduced production triggers pathomorphology changes in the brain cells in the conditions of ischemia and hypoxia.
Mexidol is the bench-mark of antioxidant neuroprotection!